More than 250 executives said that the decision ignored both scientific and legal precedent and, if it stands, would create uncertainty for the pharmaceutical and biotech industries.
View original article
Contributor: Christina Jewett
More than 250 executives said that the decision ignored both scientific and legal precedent and, if it stands, would create uncertainty for the pharmaceutical and biotech industries.
View original article
Contributor: Christina Jewett